Developing a vaccine to fight fungal infections
Official title: Task V31: Process Development for a Panfungal Vaccine
Funded at Advanced Bioscience Laboratories, INC. · NIH-11253922 · Data updated 2026-11-12
This study is working on a new vaccine to help protect people, especially those with weakened immune systems, from serious fungal infections like Candida auris and Cryptococcus neoformans, which can be tough to treat.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Advanced Bioscience Laboratories, INC. NIH-funded |
| Lab location | 1 site (Kensington, United States) |
| Project start | January 20, 2023 |
| Project end | July 30, 2025 |
| Funding year | 2025 |
| Award (this year) | $28,456 |
| NIH project number | 272201800009I-P00003-759302300001-1 |
| Project ID | NIH-11253922 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals at high risk for fungal infections, such as those with weakened immune systems or underlying health conditions.
✕Less likely to help
Patients who are not at risk for fungal infections or those who have already been effectively treated for such infections may not benefit from this research.
What this research studies
This research focuses on creating a vaccine that targets various fungal pathogens, including Candida auris and Cryptococcus neoformans, which are known for their resistance to treatment. The approach involves optimizing vaccine components and ensuring they meet regulatory standards for safety and efficacy. Patients may benefit from this research as it aims to provide a new preventive measure against serious fungal infections that can be life-threatening, especially in immunocompromised individuals.
Why it matters
Potential benefit: If successful, this research could lead to a new vaccine that significantly reduces the incidence of severe fungal infections.
How similar studies have gone: While there have been successful vaccine developments for other infectious diseases, this specific approach to a panfungal vaccine is relatively novel and has not been extensively tested.
Where this research is happening
-
Advanced Bioscience Laboratories, INC.
Kensington, United States Active
Researchers
- Principal investigator: Fouts, Tim — Advanced Bioscience Laboratories, INC.
- Study coordinator: Fouts, Tim
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.